At the ASCO 2026 Annual Meeting, clinical data from multiple pancreatic cancer KRAS inhibitors, mRNA vaccines, and immune combination therapies were disclosed in a concentrated manner. The “king of cancers” has gone nearly thirty years without a breakthrough in chemotherapy regimens. This year’s ASCO has sent a signal: the wall has finally developed a crack.
Epidemiology: The “King of Cancers” With a Survival Rate Below 12%
WHO data shows that approximately 516,000 new cases of pancreatic cancer are diagnosed globally each year, with approximately 467,000 deaths — the incidence and mortality rates are nearly identical. In China, approximately 119,000 new cases are diagnosed each year, with approximately 120,000 deaths. More than 80% of patients are diagnosed at locally advanced or metastatic stages, with a 5-year survival rate of only 9% to 12%, dropping to just 3% for those with distant metastasis. The dense stroma acts like a layer of “armor,” making it extremely difficult for chemotherapy drugs and immune cells to penetrate — this is the root cause of pancreatic cancer’s intractability.
Treatment Status: Chemotherapy Has Held the Line for Over Twenty Years, Targeted and Immune Therapies Have Repeatedly Hit Walls
Since gemcitabine was approved in 1997, chemotherapy has remained the cornerstone of advanced pancreatic cancer treatment. In 2010, the FOLFIRINOX regimen extended median overall survival (mOS) to 11.1 months, but the incidence of grade 3/4 neutropenia was as high as 46%. In 2013, nab-paclitaxel plus gemcitabine (the AG regimen) raised mOS to 8.5 months and remains one of the first-line standards to this day.
On the targeted therapy front, only patients with germline BRCA1/2 mutations (approximately 4% to 7%) can benefit from the PARP inhibitor olaparib. KRAS mutations are present in more than 90% of pancreatic ductal adenocarcinoma patients, with G12D (approximately 40%), G12V (approximately 30%), and G12R (approximately 15%) being the common subtypes, while G12C accounts for only 1% to 2%. Amgen’s sotorasib was approved in 2021, breaking the “undruggable” curse, but more than 95% of patients still have no targeted therapy available. The objective response rate of PD-1/PD-L1 monotherapy is below 5%, and the “cold tumor” characteristic renders immune monotherapy almost entirely ineffective.
ASCO 2026: Simultaneous Breakthroughs From Global and Chinese Forces
KRAS G12D Inhibitors: The Main Characters Take the Stage
Revolution Medicines’ RMC-9805 (zoldonrasib) Phase I data showed an objective response rate (ORR) of 30% and a disease control rate (DCR) of 80% in patients with KRAS G12D-mutant pancreatic cancer. The company is also advancing combination regimens with RMC-6236 (a pan-RAS inhibitor).
Chinese pharmaceutical companies are closing in fast on the KRAS track. Hengrui Pharma’s HRS-4642 (KRAS G12D inhibitor) has already initiated Phase III clinical trials, and the ASCO-disclosed data combining it with the AG regimen showed: a confirmed ORR of 41.9%, a DCR of 83.7%, and a median progression-free survival (mPFS) of 5.6 months. Jacobio’s JAB-22000 (KRAS G12D) and JAB-23400 (pan-KRAS) are also advancing rapidly.
KRAS G12C Inhibitors: Extending From Lung Cancer
Amgen’s sotorasib and BMS’s adagrasib are extending their indications from lung cancer to pancreatic cancer. In the pancreatic cancer subgroup, adagrasib reported an ORR of approximately 33% and mPFS of 5.4 months. Eli Lilly’s olomorasib (LY3537982, a KRAS G12C inhibitor) achieved an ORR of 46% and DCR of 92% in pancreatic cancer, revealing the potential of next-generation molecules.
Immune Combinations and Bispecific Antibodies: Chinese Pharmaceutical Companies Become an Important Variable
Phanes Therapeutics’ spevatamig (PT886) is a first-in-class CLDN18.2/CD47 bispecific antibody. Phase II data disclosed at ASCO 2026 show that, in combination with GnP (gemcitabine plus nab-paclitaxel) as first-line treatment for metastatic pancreatic ductal adenocarcinoma, the 2 mg/kg dose group achieved an ORR of 52.4% and DCR of 90.5%; median OS in U.S. patients reached 14.7 months, extending nearly 60% beyond historical chemotherapy data (8.5 to 9.2 months). The drug has received FDA Orphan Drug Designation and Fast Track designation, and a Phase III trial is ready to launch.
Phanes Therapeutics spevatamig (PT886) Phase II Key Data
ORR: 52.4% | DCR: 90.5%
Median OS in U.S. patients: 14.7 months (approximately 60% longer than chemotherapy)
FDA Orphan Drug Designation + Fast Track Designation
Alphamab’s KN046 (PD-L1/CTLA-4 bispecific antibody), combined with Chi-Med’s surufatinib and chemotherapy, achieved mPFS of 8.2 months and mOS of 18 months in an Ib/II phase study. Qilu Pharmaceutical’s QLS31905 (CLDN18.2/CD3 bispecific antibody) is the world’s first bispecific antibody targeting this combination to enter Phase III clinical trials, and is currently being tested in combination with chemotherapy as first-line treatment for pancreatic cancer.
mRNA Vaccines: Imagining the Journey From Adjuvant to Curative
BioNTech and Roche’s personalized mRNA vaccine Autogene cevumeran (BNT122) showed in adjuvant treatment that 50% of patients generated significant T-cell responses, with immune responders demonstrating notably superior recurrence-free survival. Hengrui’s subsidiary Ruihongdi Pharma’s RGL-270, combined with adebrelimab (a PD-L1 inhibitor), achieved a 100% 18-month recurrence-free survival rate and a 100% immune response rate in post-operative adjuvant treatment.
mRNA Vaccine Key Data
BNT122: 50% of patients generated significant T-cell responses; RFS significantly better in responders
RGL-270: 100% 18-month recurrence-free survival rate, 100% immune response rate
Other Directions
The CD40 agonist selicrelumab combined with chemotherapy showed a partial response (PR) rate of 19% in Phase I trials. Claudin 18.2 CAR-T (CT041) achieved an ORR of approximately 33%, but cytokine release syndrome (CRS) remains a challenge. The Phase III study of the tumor microenvironment-targeting drug PEGPH20 was declared a failure in 2019, indicating that pure stromal degradation is not a viable path.
Market Scale: From a “Small Pond” to a Tens-of-Billions Track
The global pancreatic cancer treatment market is currently approximately USD 3 billion to USD 3.5 billion, far below lung and breast cancer. The bottleneck is not a small patient population — it is the scarcity of effective drugs. As KRAS G12D/G12C inhibitors, mRNA vaccines, and bispecific antibodies successively receive approval, the industry projects the market could grow to USD 10 billion to USD 12 billion by 2035. If RMC-9805 or a comparable drug receives approval in 2027 to 2028, the peak sales potential of a single product could reach USD 3 billion to USD 5 billion.
However, the risk of intense competition within the track is not low. The KRAS G12D track already has at least four clinical-stage products, including RMC-9805, MRTX1133, and HRS-4642. In the bispecific antibody and CAR-T space, Chinese pharmaceutical companies and multinational giants are competing on the same stage. Whoever first establishes dual advantages in efficacy and safety will capture the largest share.
Market Forecast Snapshot
- Current global market: USD 3 billion to USD 3.5 billion
- 2035 projection: USD 10 billion to USD 12 billion
- RMC-9805 peak sales potential: USD 3 billion to USD 5 billion
Looking back from ASCO 2026, the development of new pancreatic cancer drugs is transitioning from “groping in the dark” to “following a visible trail.” KRAS-targeted breakthroughs, the entry of mRNA vaccines, ongoing exploration of immune combination therapies, and the addition of Chinese forces including Phanes Therapeutics, Hengrui, and Alphamab — the “king of cancers” no longer looks as hopeless as it did ten years ago.
Drug resistance, immunosuppressive microenvironments, and the difficulty of early diagnosis remain unavoidable obstacles. But for a tumor type that has seen few new mechanisms over thirty years, the simultaneous advancement of multiple pipelines is itself a form of progress. Patients and physicians can at least see a glimmer of dawn.
[Disclaimer]: The above content reflects analysis of publicly available information, expert insights, and BCC research. It does not constitute investment advice. BCC is not responsible for any losses resulting from reliance on the views expressed herein. Investors should exercise caution.